These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36744253)

  • 1. Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone.
    Hsueh TP; Tsai TH
    Front Pharmacol; 2023; 14():1092657. PubMed ID: 36744253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.
    Hsueh TP; Tsai TH
    BMC Complement Med Ther; 2020 Aug; 20(1):253. PubMed ID: 32799863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats.
    Lee TY; Chang HH; Chen JH; Hsueh ML; Kuo JJ
    J Ethnopharmacol; 2007 Jan; 109(2):318-24. PubMed ID: 16989967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang.
    Lee TY; Chang HH; Kuo JJ; Shen JJ
    Int J Mol Med; 2009 Apr; 23(4):477-84. PubMed ID: 19288023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.
    Yang Q; Yang F; Tang X; Ding L; Xu Y; Xiong Y; Wang Z; Yang L
    BMC Complement Altern Med; 2015 Apr; 15():122. PubMed ID: 25887351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yin-Chen-Hao-Tang ameliorates obstruction-induced hepatic apoptosis in rats.
    Lee TY; Chang HH; Wu MY; Lin HC
    J Pharm Pharmacol; 2007 Apr; 59(4):583-90. PubMed ID: 17430643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yin-Chen-Hao-Tang alleviates biliary obstructive cirrhosis in rats by inhibiting biliary epithelial cell proliferation and activation.
    Wang B; Sun MY; Long AH; Cao HY; Ren S; Bian YQ; Lu X; Gu HT; Liu CH; Liu P
    Pharmacogn Mag; 2015; 11(42):417-25. PubMed ID: 25829784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of the hepatoprotective chemical base of an orally administered herbal formulation (YCHT) in normal and CCl
    Liu H; Chen M; Yin H; Hu P; Wang Y; Liu F; Tian X; Huang C
    J Ethnopharmacol; 2019 Jun; 237():81-91. PubMed ID: 30904705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of the hepatoprotective chemical base of an orally administered herbal formulation (YCHT) in normal and CCl
    Tian X; Liu H; Qiao S; Yin H; Chen M; Hu P; Wang Y; Peng H; Liu F; Pan G; Huang C
    J Ethnopharmacol; 2019 May; 236():161-172. PubMed ID: 30802610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs.
    Jeunesse E; Woehrle F; Schneider M; Lefebvre HP
    J Vet Cardiol; 2007 Nov; 9(2):63-8. PubMed ID: 18024236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the protective effects of Yin-Chen-Hao Tang against acute liver injury induced by carbon tetrachloride using 16S rRNA gene sequencing and LC/MS-based metabolomics.
    Liu F; Sun Z; Hu P; Tian Q; Xu Z; Li Z; Tian X; Chen M; Huang C
    J Pharm Biomed Anal; 2019 Sep; 174():567-577. PubMed ID: 31261038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites.
    Sungaila I; Bartle WR; Walker SE; DeAngelis C; Uetrecht J; Pappas C; Vidins E
    Gastroenterology; 1992 May; 102(5):1680-5. PubMed ID: 1568578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Metabolomic Characterization of Liver Fibrosis in Rats and Anti-Fibrotic Effects of Yin-Chen-Hao-Tang.
    Zhang H; Wang X; Hu P; Zhou W; Zhang M; Liu J; Wang Y; Liu P; Luo G
    Molecules; 2016 Jan; 21(1):E126. PubMed ID: 26805802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
    Pérez-Ayuso RM; Arroyo V; Planas R; Gaya J; Bory F; Rimola A; Rivera F; Rodés J
    Gastroenterology; 1983 May; 84(5 Pt 1):961-8. PubMed ID: 6339312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
    Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
    J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone antagonism studies in the rhesus monkey.
    Hofmann LM; Pedrera HA; Suleymamov OD
    J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].
    Brunkhorst R; Wrenger E; Kühn K; Schmidt FW; Koch K
    Klin Wochenschr; 1989 Aug; 67(15):774-83. PubMed ID: 2671477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP; Sawinsky I; Juhos E
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.
    van Vliet AA; Hackeng WH; Donker AJ; Meuwissen SG
    J Hepatol; 1992 May; 15(1-2):40-7. PubMed ID: 1324274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.